Previous 10 | Next 10 |
PURCHASE, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that Anthony Caggiano, M.D., Ph.D. , chief medical officer and ...
Point Roberts, WA and Delta, BC - January 14, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining, Plant-Based and Tech. Today's stocks have been added to our lists o...
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that the company has been awarded a...
PURCHASE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders...
PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...
Cognition Therapeutics (NASDAQ:CGTX): Q3 GAAP EPS of -$8.12. Cash and cash equivalents of $8.3M Press Release For further details see: Cognition Therapeutics reports Q3 results
PURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...
PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the cent...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
13.5%Change Percent:
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
2024-07-29 17:15:02 ET Cantor Fitzgerald analyst issues NEUTRAL recommendation for CGTX on July 29, 2024 04:08PM ET. CGTX was trading at $1.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recom...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofila...